Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review

Immune checkpoint inhibitors are the most important new medications in oncology and include inhibitors of programmed cell death protein-1 (PD-1) such as Pembrolizumab, Nivolumab, and Cemiplimab. These anticancer agents prevent tumour immune evasion and have been associated with a range of immune-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Vickers, M. L., Seidl, B., Bigby, K., Chern, B., Eriksson, L., Hartnett, G., Gericke, C., Chew, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450342/
https://www.ncbi.nlm.nih.gov/pubmed/32908747
http://dx.doi.org/10.1155/2020/8819296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450342/
https://www.ncbi.nlm.nih.gov/pubmed/32908747
http://dx.doi.org/10.1155/2020/8819296

Ejemplares similares